Advertising
Reprints
Sponsored subscriptions
Supplements

The International Journal of Biological Markers
ISSN 0393-6155 - E-ISSN 1724-6008

THE INTERNATIONAL JOURNAL of BIOLOGICAL MARKERS publishes original contributions, editorials and current reviews dealing with basic and applied research in the field of tumor markers.

The Journal accepts contributions on the following topics which are at present a rapidly growing field of basic and clinical research:

• CIRCULATING TUMOR MARKERS
  They include all those substances secreted by cancer cells or produced by the host as a reaction against the tumor, which can be an index of tumor growth.
• CELLULAR TUMOR MARKERS
  They include all nuclear, cytoplasmatic or membrane markers studied by means of histological or cytological investigations or molecular biology techniques, that can detect any difference between normal and cancer cells.
• CELL PROLIFERATION MARKERS
  They include all markers related to cell proliferation, studied by means of autoradiographic, flow cytometric or immunohistochemical approaches, which can characterize normal and cancer cells.
• HORMONE AND GROWTH FACTOR RECEPTORS
  The study of hormone and growth factor receptors as biological markers of cancer is an attempt to correlate the presence of these physiological agents of cell regulation with the natural history of the neoplasia and other prognostic factors.
• RADIOIMMUNODETECTION This is the application in vivo of the antibodies used in vitro to detect circulating tumor markers or cellular markers. The development of immunoscintigraphy originates from the basic research ot tumor markers and can be employed as a possible approach for the diagnosis of cancer.
• IMMUNOTHERAPY
  This field includes the therapeutical utilization of the same antibodies studied in experimental models and in the clinical application of immunoscintigraphy. By labelling the antibodies with radioisotopes or with drugs it is possible to use them as antitumor agents.

Editorial staff

Editor in Chief: Massimo Gion
Co-Editors: Maria Grazie Daidone - Robin Leake
Technical Editor: Simonetta Campori

Indexing
CURRENT CONTENTS/Clinical Medicine,
Biochemistry & Biophysics Citation IndexTM,
ISI Web of Science®,
Science Citation Index-Expanded®,
ISI Alerting Services®,
Biochemistry & Biophysics Citation Index®,
Biotechnology Citation Index®,
EMBASE/Excerpta Medica,
INDEX MEDICUS/MEDLINE,
CURRENT CLINICAL CANCER,
Chemical Abstracts Service,
Biosis/Biological Abstracts®

Circulation: 1500 copies
Impact Factor 2005: 1,098
Frequency: quarterly

Editorial calendar 2011

TECHNICAL SPECIFICATIONS
Inside pages: acid-free paper matt paper, gr/sqm 90
Cover: acid free matt paper, gr/sqm 200, single coated
Binding: perfect bound

MECHANICAL REQUIREMENTS
Journal trim size: cm 21 x 28 (8 ¼ in x 11 in)
Page size: cm 21 x 28 (8 ¼ in x 11 in plus bleeds (3 mm on all sides(1/8 in) on all sides)
Double page spread:

How to supply your artwork:
Supply only a high resolution secure PDF file (at least 300 dpi, saved including all tiffs and fonts, set to CMYK).
Digital artwork can be sent by email, zipped, to:

preprint@wichtig.it specifying the journal and issue it refers to.

In alternative, send the artwork on a CD-ROM together with a progressive colour and printing proof, delivered DDP (Delivery Duty Paid) directly to the publisher, specifying the publication they are addressed to, to the following address:

Wichtig Editore Srl – Medical Publisher
Via Friuli 72
20135 Milano MI (Italy)
Tel. +39 025455122

Banner ads can be placed in our journal site, together with links to the client homepage, Banner Ads and Online Sponsorships provide you with vast exposure to your target audience with measured results.

Commercial reprints are an extremely useful tool for medical companies to promote and disseminate their activities and products within the scientific community. They offer the credibility guaranteed by the thorough peer-review process our journals stritly undergo. Commercial reprints are an exact replica of the published articles and are usually delivered within 4 working weeks.

Standard reprints are supplied in black and white or colour, printed on high quality paper, stapled and shrinkwrapped in small bundles. Standard reprints are supplied with a standard black and white cover, and they can be personalized with the Client’s code or disclaimer at no extra cost.

Customized reprintscan be personalized with the Journal’s cover, product information or company advertising in colour.
For a reprints' quotation please contact: special.sales@wichtig.it

E-prints are also available for this title. E-prints entitle the sponsor to distribute a digitial copy of the reprinted article to their own mailing list or to post a link in their website to a secure document.

Sponsored subscriptions are a direct and immediate opportunity to prove your Company's dedication to the mission of scientific research within the clinical community. Sponsored subscriptions are delivered personalized in the print edition to your selected mailing list. 

For more information and a commercial proposal on sponsored subscription, please contact: subscriptions@wichtig.it

The International Journal of Artificial Organs publishes peer-reviewed supplement issues. Supplements must be sponsored and offer an opportunity to have the sponsor's name associated with top-quality scientific material. Supplements are printed according to the standard Journal circulation and it is possible to purchase additional copies for independent distribution.
Supplements represent an outstanding opportunity to reach potential customers and emphasize the Sponsor's dedication to research and advancement.

For enquiries on supplements please contact: special.sales@wichtig.it

Supplement general guidelines

Manuscripts should be prepared in accordance with the Author Guidelines. Supplement Coordinators should submit an initial request to special.sales@wichtig.it supplying the following information:

• A brief summary of the supplement's intended subject
• A tentative Table of Contents indicating all Authors' and Contributors' names
• The name of the proposed Guest Editor for the supplement
• Target completion date for manuscripts and target release date for the supplement

The Editor in Chief has the right to reject or accept supplements. All manuscripts will be subject to review. If the Editor approves the tentative project, the coordinators will receive a full quotation directly from the Publisher. The quotation will be based on the number of manuscripts included in the supplement, the estimated final pagination, colour figures, additional copies required and any additional services which might be requested. Supplements are published online and in print.